The article discusses how Insitro, a startup using machine learning for drug discovery, is leveraging AI to potentially revolutionize the pharmaceutical industry. Insitro’s CEO, Daphne Koller, explains that their approach involves building models of diseases using data from various sources, including cells and tissues. These models aim to predict how potential drugs might interact with the disease. Koller highlights that traditional drug discovery methods are costly and inefficient, with a high failure rate. In contrast, Insitro’s AI-driven approach could lead to more targeted and effective drug candidates. The company has raised over $600 million and partnered with pharmaceutical giants like Bristol Myers Squibb. Koller emphasizes that AI won’t replace human expertise but will augment and accelerate the drug discovery process. The article explores the potential impact of AI on the pharmaceutical industry and the challenges Insitro faces in translating its technology into successful drug candidates.
Source: https://abcnews.go.com/Health/wireStory/drugs-ai-insitro-ceo-machine-learning-teach-big-116383248